Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2015

View Archived Issues

CER-001 shows safety and efficacy in FHA patients

Agilvax and Humabs BioMed to develop targeted vaccines and immunotherapies

Teva and Eagle sign license for Eagle's bendamustine rapid infusion product

Stealth BioTherapeutics initiates clinical study of Bendavia for mitochondrial myopathy

Cytori initiates phase II cell therapy trial for knee osteoarthritis

ADS-5102 leads to significant improvements in levodopa-induced dyskinesia in phase II/III study

MST-188 enhances tPA thrombolytic effect

Resolaris receives EMA orphan drug designation for FSHD

Lonza and arGEN-X sign license agreement for GS Xceed antibody-production system

OncoSec Medical and Heat Biologics to evaluate combination of immunotherapy platforms

Lead Pharma to partner with Sanofi on treatments for autoimmune diseases

FDA expands indication for Revlimid in combination with dexamethasone

Merck KGaA discloses new fatty acid synthase inhibitors

Takeda patents TYK2 inhibitors

Israelian team reports throphoblast-derived microparticles

Medipure to develop first proprietary cannabinoid formulations

Esteve presents new sigma1 receptor ligands

Ergomed enters codevelopment agreement with Dilaforette for sevuparin in sickle cell disease

Janssen patent reports new RSV antivirals

Ocera Therapeutics releases preliminary phase IIa results on OCR-002 in cirrhosis patients

TB Alliance initiates phase I trial of next-generation nitroimidazole for TB

ReveraGenBioPharma initiates phase I trial of VBP-15 for Duchenne muscular dystrophy

FDA grants priority review to cobimetinib NDA

BMS seeks approval of additional indication for Eliquis in Japan

NGF implant therapy increases the levels of cholinergic markers in AD patients

AnGes changes marketing partner in Japan for HGF gene therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...